Pfizer Reports | ELREXFIO ™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple Myeloma
“These compelling overall survival data support the clinical benefit ELREXFIO [...]
“These compelling overall survival data support the clinical benefit ELREXFIO [...]
“After more than five years, the CAPTIVATE study findings confirm [...]
“These data confirm the observations from our prior clinical readouts [...]
Dr. Hui Zhou, Senior Vice President of Innovent, stated: “IBI363, [...]
Favorable patient outcomes from the TANDEM I first-in-human clinical trial [...]
Deciphera Pharmaceuticals notes the article titled “Vimseltinib versus placebo for [...]
Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a [...]
The study is designed to assess the clinical utility and [...]
Medical device and technology company Lazurite® announced that a new [...]
Based on NAPT member survey data and other sources, “Temporal [...]